151 related articles for article (PubMed ID: 12116552)
21. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction.
Salem EA; Kendirci M; Hellstrom WJ
Curr Opin Investig Drugs; 2006 Jul; 7(7):661-9. PubMed ID: 16869121
[TBL] [Abstract][Full Text] [Related]
22. Clinical evaluation of erectile dysfunction in the era of PDE-5 inhibitors.
Lobo JR; Nehra A
Urol Clin North Am; 2005 Nov; 32(4):447-55, vi. PubMed ID: 16291036
[TBL] [Abstract][Full Text] [Related]
23. Vasoactive pharmacotherapy to cure erectile dysfunction: fact or fiction?
Burnett AL
Urology; 2005 Feb; 65(2):224-30. PubMed ID: 15708027
[No Abstract] [Full Text] [Related]
24. Tadalafil Lilly ICOS.
Rotella DP
Curr Opin Investig Drugs; 2003 Jan; 4(1):60-5. PubMed ID: 12625031
[TBL] [Abstract][Full Text] [Related]
25. Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon?
Lincoln TM
Mol Pharmacol; 2004 Jul; 66(1):11-3. PubMed ID: 15213291
[No Abstract] [Full Text] [Related]
26. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
27. PDE-5 inhibitors: current status and future trends.
Masson P; Lambert SM; Brown M; Shabsigh R
Urol Clin North Am; 2005 Nov; 32(4):511-25, viii. PubMed ID: 16291042
[TBL] [Abstract][Full Text] [Related]
28. An update on the PDE-5 inhibitors (PDE-5i).
McCullough AR
J Androl; 2003; 24(6 Suppl):S52-8. PubMed ID: 14581496
[No Abstract] [Full Text] [Related]
29. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
Eardley I
Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
[No Abstract] [Full Text] [Related]
30. [How I treat and manage erectile dysfunction in diabetics].
Buvat J
Journ Annu Diabetol Hotel Dieu; 2006; ():185-203. PubMed ID: 17051861
[No Abstract] [Full Text] [Related]
31. Salvage techniques for phosphodiesterase 5 inhibitor therapy: purposeful but how much?
Burnett AL
Eur Urol; 2006 Jul; 50(1):29-30. PubMed ID: 16567036
[No Abstract] [Full Text] [Related]
32. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy.
Nehra A; Grantmyre J; Nadel A; Thibonnier M; Brock G
J Urol; 2005 Jun; 173(6):2067-71. PubMed ID: 15879836
[TBL] [Abstract][Full Text] [Related]
33. [After taking the table, immediate sex? New potency pill allows more time for love life].
MMW Fortschr Med; 2004 May; 146(19):64. PubMed ID: 15357491
[No Abstract] [Full Text] [Related]
34. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
35. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
Vickers MA; Satyanarayana R
Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
[TBL] [Abstract][Full Text] [Related]
36. Commentaries on Jackson et al. "Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction".
Kloner RA; Montorsi P; DeBusk RF
J Sex Med; 2005 Sep; 2(5):740-2; author reply 742. PubMed ID: 16422835
[No Abstract] [Full Text] [Related]
37. Erectile dysfunction and cardiovascular considerations: managing patients effectively with phosphodiesterase type 5 inhibitors.
Hutter AM
Clin Cardiol; 2004 Apr; 27(4 Suppl 1):I1-2. PubMed ID: 15115188
[No Abstract] [Full Text] [Related]
38. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Patel MD; Katz SD
Am J Cardiol; 2005 Dec; 96(12B):47M-51M. PubMed ID: 16387567
[TBL] [Abstract][Full Text] [Related]
39. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
Shabsigh R; Seftel AD; Rosen RC; Porst H; Ahuja S; Deeley MC; Garcia CS; Giuliano F
Urology; 2006 Oct; 68(4):689-96. PubMed ID: 17070333
[No Abstract] [Full Text] [Related]
40. The use of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Montorsi F; Briganti A; Salonia A; Montorsi P; Rigatti P
Curr Opin Urol; 2004 Nov; 14(6):357-9. PubMed ID: 15626879
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
